Cargando…

Feasibility Study of a Modified XELOX Adjuvant Chemotherapy for High-Recurrence Risk Patients With Operated Stage III Colon Cancer

BACKGROUND: Our previous study reported the favorable efficacy and good tolerance associated with a modified XELOX adjuvant chemotherapy with eight cycles of capecitabine and six cycles of oxaliplatin for operated stage III colon cancer. The current study aimed to confirm the feasibility of modified...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Jianhong, Li, Weihao, Fan, Wenhua, Zhou, Wenhao, Zhu, Ying, Li, Xueying, Pan, Zhizhong, Lin, Xiaoping, Lin, Junzhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543913/ https://www.ncbi.nlm.nih.gov/pubmed/33071795 http://dx.doi.org/10.3389/fphar.2020.583091

Ejemplares similares

Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience
por: Peng, Jianhong, et al.
Publicado: (2019)

High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy
por: Zhou, Wenhao, et al.
Publicado: (2019)

Efficacy of XELOX adjuvant chemotherapy for gastric mixed adenoneuroendocrine carcinoma: A case report
por: Lin, Zhixian, et al.
Publicado: (2019)

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
por: Ruzzo, Annamaria, et al.
Publicado: (2019)

Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis
por: Huang, Wen-Kuan, et al.
Publicado: (2021)

Surgical Outcomes of Robotic Resection for Sigmoid and Rectal Cancer: Analysis of 109 Patients From a Single Center in China
por: Peng, Jianhong, et al.
Publicado: (2021)

Application of Tumor Burden Score for predicting conversion outcome in patients with initially unresectable colorectal liver metastases after first-line systemic therapy
por: Peng, Jianhong, et al.
Publicado: (2021)

Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
por: Yu, Shan, et al.
Publicado: (2020)

Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX
por: Yin, Xin, et al.
Publicado: (2020)

Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
por: Ruzzo, Annamaria, et al.
Publicado: (2020)

Long-Term Outcome of Oxaliplatin and Capecitabine (XELOX) Concomitant with Neoadjuvant Radiotherapy and Extended to the Resting Period in High Risk Locally Advanced Rectal Cancer
por: Tang, Jinghua, et al.
Publicado: (2018)

Right- and left-sided stage III colon cancers present different prognostic outcomes of oxaliplatin-based adjuvant chemotherapy after curative resection
por: Peng, Jianhong, et al.
Publicado: (2018)

Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients
por: Zhang, Linjie, et al.
Publicado: (2023)

Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?
por: Pan, Zhizhong, et al.
Publicado: (2018)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer
por: Yu, Yuanyuan, et al.
Publicado: (2022)

Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2017)

Construction of Nomogram-Based Prediction Model for Clinical Prognosis of Patients with Stage II and III Colon Cancer Who Underwent Xelox Chemotherapy after Laparoscopic Radical Resection
por: Sun, Qiang, et al.
Publicado: (2022)

Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer
por: Peng, Jianhong, et al.
Publicado: (2021)

Whether Patients With Stage Ⅱ/Ⅲ Colorectal Cancer Benefit From Adjuvant Chemotherapy: A Modeling Analysis of Literature Aggregate Data
por: Zha, Sijie, et al.
Publicado: (2022)

Comparison of S‐1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single‐center retrospective study
por: Jiang, Zhichao, et al.
Publicado: (2020)

Efficacy and safety of neoadjuvant imatinib therapy for patients with locally advanced rectal gastrointestinal stromal tumors: A multi-center cohort study
por: Li, Weihao, et al.
Publicado: (2022)

The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer
por: Chen, Jun-Bing, et al.
Publicado: (2022)

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
por: André, Thierry, et al.
Publicado: (2013)

Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
por: Tian, Yuan, et al.
Publicado: (2021)

Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school
por: Ungari, Andrea Queiróz, et al.
Publicado: (2017)

The Pathologic Complete Response Ratio of Liver Metastases Represents a Valuable Prognostic Indicator
por: Xu, Yanbo, et al.
Publicado: (2022)

A Report of Disseminated Carcinomatosis of the Bone Marrow Originating from Transverse Colon Cancer Successfully Treated with Chemotherapy Using XELOX plus Bevacizumab
por: Naito, Masayasu, et al.
Publicado: (2014)

A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis
por: Wang, Yan, et al.
Publicado: (2014)

Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer
por: Karim, Safiya, et al.
Publicado: (2019)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
por: Khalil, Lana, et al.
Publicado: (2022)

Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study)
por: Chen, Yizhang, et al.
Publicado: (2023)

The survival benefit of intensified full-dose XELOX chemotherapy concomitant to radiotherapy and then resting-period consolidation chemotherapy in locally advanced rectal cancer
por: Zheng, Rong, et al.
Publicado: (2019)

A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX
por: Zhu, Jiangpeng, et al.
Publicado: (2023)

Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage III colon cancer
por: Jeong, Woon Kyung, et al.
Publicado: (2015)

Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?
por: Roda, Desamparados, et al.
Publicado: (2018)

Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients
por: Boakye, Daniel, et al.
Publicado: (2021)

Efficacy and safety of Omega-3 polyunsaturated fatty acids in adjuvant treatments for colorectal cancer: A meta-analysis of randomized controlled trials
por: Liu, Haoshuang, et al.
Publicado: (2023)

Efficacy and safety of a NiTi CAR 27 compression ring for end-to-end anastomosis compared with conventional staplers: A real-world analysis in Chinese colorectal cancer patients
por: Lu, Zhenhai, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dfa8c6c2libi6jd58adjpoo9ju